Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Source: View publication →
The EXPLORER-HCM trial demonstrated that the first-in-class cardiac myosin inhibitor, mavacamten, significantly improved exercise capacity, NYHA functional class, and disease-related symptoms in patients with symptomatic obstructive hypertrophic cardiomyopathy compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
Mavacamten represents the first disease-specific, targeted pharmacological intervention for obstructive hypertrophic cardiomyopathy that directly addresses the underlying pathophysiologic mechanism of cardiac hypercontractility. This therapy provides a viable medical alternative to invasive septal reduction therapies and improves quality of life for patients who are symptomatic despite conventional medical management.
Historical Context
For several decades, management of symptomatic obstructive hypertrophic cardiomyopathy relied on non-specific agents such as beta-blockers, calcium channel blockers, and disopyramide, which often offered suboptimal symptom relief and carried significant tolerability issues. EXPLORER-HCM was a landmark study that introduced the concept of myosin inhibition to precisely target the sarcomere dysfunction characteristic of the disease, marking a paradigm shift in the therapeutic landscape of HCM.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of mavacamten, a cardiac myosin inhibitor, specifically target the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM) compared to traditional therapies like beta-blockers?
Key Response
Hypertrophic cardiomyopathy is characterized by hypercontractility and impaired relaxation due to an excess of myosin-actin cross-bridges in the 'on' position. Mavacamten shifts the myosin population toward a 'super-relaxed' state, reducing the number of active cross-bridges. In contrast, beta-blockers primarily address the symptoms by slowing heart rate to increase diastolic filling time and reducing the force of contraction via sympathetic blockade, but they do not directly inhibit the molecular motor protein responsible for the disease.
In a patient with symptomatic oHCM despite maximally tolerated beta-blocker therapy, what specific clinical criteria from the EXPLORER-HCM trial would make them a candidate for mavacamten therapy?
Key Response
Candidates for mavacamten in the EXPLORER-HCM trial were adults with symptomatic oHCM (NYHA class II or III) who had an LVOT gradient of 50 mmHg or more (at rest or provoked) and a left ventricular ejection fraction (LVEF) of at least 55%. Residents must also be aware that initiating mavacamten requires regular LVEF monitoring due to its potent effect on contractility, as the trial demonstrated a reversible decrease in LVEF in some participants.
The EXPLORER-HCM trial reported a significant reduction in NT-proBNP and high-sensitivity cardiac troponin I levels. Discuss how these biomarkers reflect the hemodynamic changes induced by mavacamten and their potential prognostic value in managing long-term remodeling.
Key Response
NT-proBNP is a marker of myocardial wall stress, while troponin reflects myocardial injury. The reduction in these markers (NT-proBNP by 80% compared to placebo) indicates that mavacamten effectively relieves the LVOT gradient and reduces intra-cardiac pressures. For the subspecialist, this suggests that the drug may not just provide symptomatic relief but could potentially mitigate the long-term adverse remodeling that leads to heart failure and arrhythmias in HCM patients.
Mavacamten is subject to a Risk Evaluation and Mitigation Strategy (REMS) program. Given the EXPLORER-HCM safety data, how do you approach the conversation with a patient regarding the 'trade-off' between symptomatic improvement and the risk of developing heart failure with a reduced ejection fraction?
Key Response
In the trial, 7% of the mavacamten group experienced an LVEF drop to below 50%, which was reversible upon drug discontinuation. The 'wise' clinical approach involves educating patients on the necessity of strict echocardiographic monitoring every 4 to 12 weeks. The attending must weigh the 'procedural' risk of septal reduction therapy (myectomy/alcohol ablation) against the 'pharmacological' risk of reversible systolic dysfunction and the logistical burden of the REMS program.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of the primary composite functional endpoint in EXPLORER-HCM (improvement in pVO2 and NYHA class) versus a hard clinical outcome like cardiovascular mortality or hospitalization. How might the exclusion of patients with atrial fibrillation limit the generalizability of these statistical findings?
Key Response
Using pVO2 and NYHA class allows for a smaller sample size and shorter trial duration to show efficacy in a rare disease. However, NYHA is subjective and pVO2 changes of 1.1 mL/kg/min, while statistically significant, may have questionable clinical impact. Excluding AF patients—who represent a significant portion of the HCM population—limits the generalizability of the safety and efficacy data, as rhythm disturbances can complicate both the assessment of pVO2 and the risk profile of myosin inhibitors.
If you were the primary reviewer for this manuscript, how would you address the potential for unblinding due to the drug's potent effects on the LVOT gradient, and what concerns would you raise regarding the internal validity of the NYHA class assessments?
Key Response
A tough reviewer would flag that because mavacamten significantly reduces the LVOT gradient—a measurement frequently seen by the clinical staff performing echos—unblinding could occur, potentially biasing the subjective NYHA class reporting. Editors look for 'core laboratories' and blinded assessment committees to mitigate this; however, the physiological 'tell' of the drug (the gradient drop) remains a threat to the rigor of a double-blind design.
Based on the EXPLORER-HCM evidence, should mavacamten be recommended as a first-line therapy, or should it remain a Class IIa/IIb alternative to septal reduction therapy in the next update to the AHA/ACC Hypertrophic Cardiomyopathy guidelines?
Key Response
Current guidelines (2020 AHA/ACC) place beta-blockers and calcium channel blockers as first-line for symptomatic oHCM. Mavacamten provides a robust pharmacological alternative for patients who fail first-line therapy but wish to avoid or are not candidates for invasive septal reduction therapy. The committee must decide if the high cost and REMS monitoring requirements justify a Level A recommendation or if it should be reserved for those specifically 'refractory' to traditional medical therapy.
Clinical Landscape
Noteworthy Related Trials
PIONEER-HCM Trial
Tested
Mavacamten
Population
Symptomatic obstructive HCM patients
Comparator
Open-label study (no formal placebo comparator)
Endpoint
Change in peak oxygen consumption (pVO2)
MAVERICK-HCM Trial
Tested
Mavacamten
Population
Symptomatic non-obstructive HCM patients
Comparator
Placebo
Endpoint
Safety and tolerability
VALOR-HCM Trial
Tested
Mavacamten
Population
Symptomatic obstructive HCM patients eligible for septal reduction therapy
Comparator
Placebo
Endpoint
Composite of death, SRT, or eligibility for SRT at week 16
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis